The estimated Net Worth of Andy Porter is at least $410 Thousand dollars as of 28 October 2022. Mr Porter owns over 448 units of Relay Therapeutics stock worth over $350,473 and over the last 3 years he sold RLAY stock worth over $59,044.
Mr has made over 7 trades of the Relay Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 448 units of RLAY stock worth $9,650 on 28 October 2022.
The largest trade he's ever made was selling 452 units of Relay Therapeutics stock on 28 July 2022 worth over $9,614. On average, Mr trades about 302 units every 38 days since 2021. As of 28 October 2022 he still owns at least 45,164 units of Relay Therapeutics stock.
You can see the complete history of Mr Porter stock trades at the bottom of the page.
Andy Porter is the Exec. VP & Chief People Officer at Relay Therapeutics.
Andy's mailing address filed with the SEC is C/O RELAY THERAPEUTICS, INC., 399 BINNEY ST., 2ND FLOOR, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Relay Therapeutics have traded over $234,228,237 worth of Relay Therapeutics stock and bought 110,000 units worth $2,200,000 . The most active insiders traders include Rock Ventures Iii, L.P.Thir..., Sanjiv Patel, and Donald A Bergstrom. On average, Relay Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $406,570. The most recent stock trade was executed by Thomas Catinazzo on 29 July 2024, trading 10,780 units of RLAY stock currently worth $92,277.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics executives and other stock owners filed with the SEC include: